Data drip sheds little light on how Ionis, AstraZeneca compare to Alnylam in rare disease

Ionis Pharmaceuticals has dropped more data on its AstraZeneca-partnered treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN), shedding a little more light on how the antisense candidate matches up to Alnylam’s incumbents.